SCSilvia Calabria

Silvia Calabria

*This is an algorithmically generated author record based on publicly available information.

Silvia Calabria has a total of 125 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Treatment Switching and Drug Survival of Biologic Therapies in Psoriasis: A Real-World Italian Study Across Biologic Classes

    by Silvia Calabria, Paolo Gisondi, Marina Talamonti, Lorenzo Giovanni Mantovani, Chiara Veronesi, Luca Degli Esposti

    Background/Objectives: Psoriasis is a chronic inflammatory skin disease leading to substantial psycho-physical and social burden and reduced quality of life. Biologic agents have transformed its therapeutic landscape. This real-world Italian study described the pattern of treatment with biologic drugs in patients with psoriasis. Methods: A retrospective observational study was conducted using administrative databases from Italian Local Health Units, covering nearly 12 million individuals. The study included adults with psoriasis identified from January 2015 to March 2025 by hospitalization, co-payment exemption code, or topical anti-psoriatic prescriptions. Patients initiating a biologic drug (anti-TNFα, anti-IL12/23, anti-IL17, and anti-IL23) were selected and further analyzed in terms of treatment switching, drug survival, and healthcare resource utilization and related costs within the first year after biologic initiation, and compared. Results: A total of 10,270 biologic-naïve adult patients was included in the analysis (anti-TNFα N = 5078; anti-IL12/23 N = 767; anti-IL17 N = 2574; anti-IL23 N = 1851). Most patients (95.0%) starting an anti-IL23 agent did not switch. Compared with anti-TNFα, initiating an anti-IL23 inhibitor was associated with a significant reduced risk of switching (HR = 0.186; 95%CI: 0.144–0.240; p < 0.001). According to the cost analysis stratified by switching status, remaining on the index biologic was associated with a lower economic burden. Although differences between switchers vs. non-switchers among anti-IL23 users did not reach statistical significance (€12,052 vs. €11,406, respectively, p = 0.132), data support the economic advantage associated with greater treatment stability. Conclusions: Anti-IL23 agents showed effective, durable first-line use with potential long-term clinical and economic benefits in moderate-to-severe psoriasis.

  • Missed Opportunities in the Therapeutic Patterns of Chronic Obstructive Pulmonary Disease: A Real-World Italian Study on the Impact of Severe Exacerbation on Mortality and Hospital Re-admission

    by Giulia Ronconi, Letizia Dondi, Leonardo Dondi, Silvia Calabria, Irene Dell’ANno, Ovidio Brignoli, Fabiano Di Marco, Claudio Micheletto, Nello Martini, Carlo Piccinni

    Patients experiencing severe exacerbation (SE) of chronic obstructive pulmonary disease (COPD) face high re-hospitalization and mortality rates. Knowing their impact on health services is crucial for making decisions and improving the care pathway for these patients. To describe mortality, re-hospitalizations and therapeutic patterns of patients experiencing SE, this study used real-world Italian administrative data and examined pre- and post-SE treatment patterns. From an Italian administrative database (4.6 million inhabitants), patients with COPD in 2022 were identified, and those experiencing SE requiring hospitalization were described in terms of demographics, comorbidities, 12-month mortality and re-hospitalization rates, and therapeutic patterns during 12 months pre- and post-SE. Treatment patterns included dispensations of single-inhaler (SI, i.e., fixed-dose combination) triple therapy (TT), multiple-inhaler (MI, i.e., open combination) TT, dual therapy (DT; based on combinations between inhaled corticosteroid/long-acting beta-agonist/muscarinic antagonist), other respiratory treatment strategies, and no treatment. Among 81,571 patients with COPD (32.1 per 1000 inhabitants aged ≥ 45 years), patients experiencing SE were 6.2% (5080 patients with COPD): mean age was 77 years, 63.4% (3220 patients with SE) were male and 68.2% (3467 patients with SE) had ≥ 3 comorbidities. Mean in-hospital length of stay was 11.9 days. One-year mortality rate was 25.6% (1302 patients with SE), mainly within the first month, 76.0% (989 deaths) of which occurred in hospital. Among 12-month analysable patients (3778), the 12-month re-hospitalization rate was 20.1% (761 patients with SE and alive) occurring, on average, at 155 days (16.4% within the first month). Pre/post SE, single-inhaler triple therapy (SI-TT) and multiple-inhaler triple therapy (MI-TT) increased from 1.4 to 23.4% and from 1.2 to 6.3% patients, respectively; DT, other strategies, and no treatment reduced from 24.5 to 22.5%, 35.7 to 23.8% and 37.1 to 24.0%, respectively. On average, TT was initiated at ≥ 31 days post-SE. Mean time to TT initiation was approximately 31-42 days depending on prior therapy, although most patients initiated TT within the first 30 days. A substantial proportion of patients experiencing SE of COPD were re-hospitalised or remained inadequately treated or untreated, despite a high mortality rate. These findings underscore the necessity for a more appropriate and prompt therapeutic intervention.


  • Open Access

    Healthcare of patients with immunoglobulin A nephropathy through a retrospective observational study of Italian administrative data

    by Luigi Biancone, Gaetano La Manna, Letizia Dondi, Leonardo Dondi, Giulia Ronconi, Silvia Calabria, Irene Dell'ANno, Carlo Piccinni, Immacolata Esposito, Alice Addesi, et al.

    Background: Immunoglobulin A nephropathy (IgAN) is a rare disease poorly described in real-world settings. Thisobservational retrospective study aimed to assess the direct healthcare burden of new IgAN patients on the ItalianNational Healthcare Service (SSN).Methods: From the Fondazione Ricerca e Salute’s database (administrative healthcare data of ~5.5 millioninhabitants/year), inpatients with new potential in-hospital biopsy-verified IgAN from 2016 to 2019 were identified.Dispensations of IgAN-recommended and other drugs, kidney replacement therapies (KRT), hospitaland emergency department (ED) admissions, local outpatient specialist care, and related direct costs wereassessed throughout a 3-year follow-up.Results: New IgAN patients (n = 292) were identified (incidence/year: 1.25/100 000 inhabitants); 64% of patientswere male; the median age was 41 (27; 57) years. Annual consumption of most healthcare resources decreasedfrom Year 1 to 3: from 90% to 84% of patients received ≥1 IgAN-recommended drug; from 100% (due to selectioncriteria) to 15% of patients underwent overnight hospitalizations; from 8% to 3% patients underwent dayhospitalizations; from 31% to 21% patients underwent ≥1 ED access; from 87% to 85% patients received local outpatient specialist services. Of all patients, 2–4% were treated with KRT, and ~91% received other drugs. The percapita mean total annual cost was €7441 in Year 1 (hospitalizations accounting for 73% due to selection criteria),€3497 in Year 2, and €3243 in Year 3 (drugs accounting for 51%, mostly attributable to other drugs).Conclusion: This real-world study shows a substantial direct healthcare burden for new IgAN patients arising fromIgAN-specific care and comorbidities.

  • Open Access

    A retrospective observational analysis of the real-world care pathway of people with hereditary transthyretin amyloidosis with polyneuropathy in Italy

    by Silvia Calabria, Giulia Ronconi, Letizia Dondi, Leonardo Dondi, Irene Dell’aNno, Carlo Piccinni, Immacolata Esposito, Alice Addesi, Marco Gnesi, Nicola Cosentino, et al.

    This retrospective observational study described the epidemiology and the burden on the Italian healthcare service (SSN) of patients with polyneuropathy (PN) associated to the hereditary transthyretin amyloidosis (ATTRv). From the Fondazione ReS (Ricerca e Salute) administrative healthcare database (~5.5 million inhabitants in 2021), patients were identified as having ATTRv-PN in 2021 if they had received treatments for ATTRv-PN under SSN reimbursement (i.e. tafamidis, patisiran or inotersen) from 1 January 2014 to 12/31/2021 (index date in 2021). Demographics and comorbidities at baseline, healthcare resource consumptions and related direct costs reimbursed by the SSN throughout one-year follow-up were described. In 2021, 36 patients with ATTRv-PN (prevalence: 7.4/1,000,000) were identified (males were 83.3%; patients with ≥ 2 comorbidities were 61.1%; mean age was 73 ± 8 years). During follow-up, of patients: 91.7% received drugs for ATTRv-PN; >50% received antiepileptics and acid suppressants; 22.2% were admitted to overnight hospitalizations; 30.6% accessed the emergency department; 97.2% received local outpatient specialist care. The per patient mean annual cost was € 122,017; drugs for ATTRv-PN accounted for 94.7% of the total expenditure. This study of real-world patients with ATTRv-PN showed a high rate of comorbidities, and substantial direct healthcare and economic burdens on the SSN.


  • Open Access

    Correction: Clinical characteristics, use and switch of drugs for obstructive airway diseases among patients with COPD experiencing an exacerbation: a retrospective analysis of Italian administrative healthcare data

    by Letizia Dondi, Giulia Ronconi, Silvia Calabria, Irene Dell’aNno, Leonardo Dondi, Carlo Piccinni, Ovidio Brignoli, Giorgio Walter Canonica, Mauro Carone, Fabiano Di Marco, et al.


  • Open Access

    Clinical characteristics, use and switch of drugs for obstructive airway diseases among patients with COPD experiencing an exacerbation: a retrospective analysis of Italian administrative healthcare data

    by Letizia Dondi, Giulia Ronconi, Silvia Calabria, Irene Dell’aNno, Leonardo Dondi, Carlo Piccinni, Ovidio Brignoli, Giorgio Walter Canonica, Mauro Carone, Fabiano Di Marco, et al.

    Chronic obstructive pulmonary disease (COPD) represents an important health challenge, despite being preventable and manageable thanks to up-to-date recommendations. In Italy, the pharmaceutical care of COPD patients is still ill-timed and inaccurate. This study aimed to describe the treatment of COPD patients in Italy and possible switches following an exacerbation. This observational retrospective analysis of Italian administrative healthcare data from the Fondazione Ricerca e Salute (ReS) database identified patients aged ≥ 45 years with COPD in 2019 and 2020. At least 6 years of look-back period and absence of concomitant asthma were required. COPD patients were categorized by treatment (SI–single/MI–multiple inhalers, TT–triple therapy, DT–dual therapy, other respiratory treatments, untreated) at index date (first dispensation during accrual period). Occurrence of moderate/severe exacerbation during one-year preceding index date and treatments during one-year preceding the exacerbation (possible switch) were evaluated. From ~ 4.7 million beneficiaries of the Italian National Health Service in 2019 and 2020, respectively, 105,828 and 103,729 (43 and 41 × 1,000 inhabitants aged ≥ 45 years) were identified as having COPD. Of 2019/2020 patients: 3.4%/5.2% received SI-TT, 20.7%/17.5% MI-TT, 35.9%/38.1% DT, 33.0%/33.1% other treatments, and 7.0%/6.0% were untreated. Males were prevalent and median age was > 73 years for all groups. Of 2019/2020 cohorts, heart failure and coronary artery disease affected 24/20%, 18/17%, and 11%/16% patients with SI-TT, MI-TT, DT, and other treatments, respectively. A previous moderate/severe exacerbation (2019/2020 patients) occurred to 60.5%/56.6%, 39.9%/37.4%, 30.8%/29.2% and 31.9%/29.7% patients treated with SI-TT, MI-TT, DT, and other treatments, respectively. Of 2019/2020 patients experiencing moderate/severe exacerbation: 6.0%/7.0% receiving DT, 5.1%/7.0% receiving other treatments and 4.5%/10.0% untreated, switched to SI-TT; 23.7%/16.9% receiving DT, 21.4%/17.7% receiving other treatments and 15.4%/12.0% untreated, switched to MI-TT. COPD patients receiving TT were older and had more comorbidities, especially cardiovascular diseases, than patients receiving DT or other treatments. The limited number of patients switching after exacerbation suggests that many COPD patients may be inappropriately treated. Ensuring early and adequate treatment, combination of in-hospital and outpatient management, and integration of specialist and primary care is pivotal for the appropriate clinical management of COPD patients.


  • Open Access

    Italian healthcare resource consumptions and direct costs of adults with atopic dermatitis before and after dupilumab treatment

    by Giulia Ronconi, Letizia Dondi, Silvia Calabria, Leonardo Dondi, Antonella Pedrini, Immacolata Esposito, Maria Scattareggia, Paola Rogliani, Matteo Trimarchi, Antonio Costanzo, et al.

    Article: Italian healthcare resource consumptions and direct costs of adults with atopic dermatitis before and after dupilumab treatment - Italian Journal of Dermatology and Venereology 2024 August;159(4):417-24 - Minerva Medica - Journals


  • Open Access

    Primary Sjögren's syndrome in Italy: Real-world evidence of a rare disease through administrative healthcare data

    by Giacomo Cafaro, Carlo Perricone, Giulia Ronconi, Silvia Calabria, Letizia Dondi, Leonardo Dondi, Antonella Pedrini, Immacolata Esposito, Roberto Gerli, Elena Bartoloni, et al.


  • Open Access

    Italian healthcare resource consumption for patients on hemodialysis treated for chronic kidney disease-associated pruritus (CKD-aP)

    by Silvia Calabria, Manenti Lucio, Giulia Ronconi, Carlo Piccinni, Leonardo Dondi, Letizia Dondi, Antonella Pedrini, Immacolata Esposito, Alice Addesi, Filippo Aucella, et al.

    Background: Chronic kidney disease-associated pruritus (CKD-aP) affects patients on hemodialysis. This study identified hemodialysis patients presumably affected or not affected by CKD-aP and integrated healthcare costs, from the perspective of the Italian administrative healthcare data. Methods: Through cross-linkage of Italian administrative healthcare data collected between 2015 and 2017 (accrual period) in the database of Fondazione ReS (Ricerca e Salute), patients undergoing in-hospital/outpatient hemodialysis were selected. Cohorts with and without CKD-aP were created based on the presence/absence of CKD-aP-related treatment (according to common clinical practice and guidelines) supplies and assessed in terms of CKD-aP-related treatments and mean healthcare costs per capita paid by the Italian National Health Service (INHS). Results: Of 1,239 people on hemodialysis for ≥2 years, CKD-aP affected 218 patients. Patients with CKD-aP were older and with more comorbidities. During the follow-up year, on average, the INHS spent €37,065 per case, €31,286 per control and € 35,988 per non-CKD-aP subject. High-efficiency dialytic therapies performed to people on hemodialysis with CKD-aP largely weighed on the overall mean annual cost. Conclusions: This real-world study identified patients on chronic hemodialysis potentially treated for CKD-aP. Interestingly, high-efficiency dialysis seems the most frequent and expensive choice for the treatment of CKD-aP. The discovery of appropriate and effective treatments for this condition might offer cost offsets.


  • Open Access

    Do more targets allow more cancer treatments, or not?

    by Paolo Marchetti, Giuseppe Curigliano, Silvia Calabria, Carlo Piccinni, Andrea Botticelli, Nello Martini